{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:38:14Z","timestamp":1791999494672,"version":"4.4.0"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T00:00:00Z","timestamp":1710460800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Collagenase Clostridium histolyticum (CCH) remains the only Food and Drug Administration\u2013approved medical treatment for Peyronie\u2019s disease (PD). The initial IMPRESS I and II trials (Investigation for Maximal Peyronie\u2019s Reduction Efficacy and Safety), which led to Food and Drug Administration approval, revealed a rate of treatment-related adverse events as high as 84%. Studies fail to provide clear definitions of complications.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To review complications, provide a CCH complication atlas, and propose management strategies for commonly encountered complications.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We performed a literature review using PubMed. A photographic atlas was provided regarding complications in patients in a high-volume CCH center for PD.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Complications were identified and classified by nature and severity. We followed a standardized previously published grading system for hematomas. Complications include bruising, swelling, hematoma formation, back pain, and, rarely, corporal rupture. Complications were discussed, and hematomas were graded by penile surface area. Complication photographs were graded and displayed. Treatment-related adverse effects do not affect overall results.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Recognizing and grading complications associated with CCH therapy for PD is crucial for effective patient management and informed decision making. A standardized grading system allows for consistency in reporting and comparing hematoma complication rates across studies and patient populations. Herein we provide images that will help clinicians identify and confidently manage common complications that may occur in any CCH program.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/sxmrev\/qeae004","type":"journal-article","created":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T04:47:15Z","timestamp":1706590035000},"page":"491-496","source":"Crossref","is-referenced-by-count":5,"title":["Collagenase <i>Clostridium histolyticum<\/i> for Peyronie\u2019s disease: a contemporary atlas of complications and their management"],"prefix":"10.1093","volume":"12","author":[{"given":"Thiago P","family":"Furtado","sequence":"first","affiliation":[{"name":"Division of Andrology , Department of Urology, David Geffen School of Medicine, , Los Angeles, CA, 90095 , United States"},{"name":"University of California, Los Angeles , Department of Urology, David Geffen School of Medicine, , Los Angeles, CA, 90095 , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vadim","family":"Osadchiy","sequence":"additional","affiliation":[{"name":"Division of Andrology , Department of Urology, David Geffen School of Medicine, , Los Angeles, CA, 90095 , United States"},{"name":"University of California, Los Angeles , Department of Urology, David Geffen School of Medicine, , Los Angeles, CA, 90095 , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan J","family":"Andino","sequence":"additional","affiliation":[{"name":"Division of Andrology , Department of Urology, David Geffen School of Medicine, , Los Angeles, CA, 90095 , United States"},{"name":"University of California, Los Angeles , Department of Urology, David Geffen School of Medicine, , Los Angeles, CA, 90095 , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sriram V","family":"Eleswarapu","sequence":"additional","affiliation":[{"name":"Division of Andrology , Department of Urology, David Geffen School of Medicine, , Los Angeles, CA, 90095 , United States"},{"name":"University of California, Los Angeles , Department of Urology, David Geffen School of Medicine, , Los Angeles, CA, 90095 , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse N","family":"Mills","sequence":"additional","affiliation":[{"name":"Division of Andrology , Department of Urology, David Geffen School of Medicine, , Los Angeles, CA, 90095 , United States"},{"name":"University of California, Los Angeles , Department of Urology, David Geffen School of Medicine, , Los Angeles, CA, 90095 , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,3,15]]},"reference":[{"issue":"3","key":"2024070101015365900_ref1","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.juro.2015.05.098","article-title":"Peyronie\u2019s disease: AUA guideline","volume":"194","author":"Nehra","year":"2015","journal-title":"J Urol"},{"issue":"2","key":"2024070101015365900_ref2","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00345-019-02815-6","article-title":"A review of inflammation and fibrosis: implications for the pathogenesis of Peyronie\u2019s disease","volume":"38","author":"Patel","year":"2020","journal-title":"World J Urol"},{"issue":"1","key":"2024070101015365900_ref3","doi-asserted-by":"crossref","first-page":"46","DOI":"10.21037\/tau.2016.11.01","article-title":"Understanding the cellular basis and pathophysiology of Peyronie\u2019s disease to optimize treatment for erectile dysfunction","volume":"6","author":"Campbell","year":"2017","journal-title":"Transl Androl Urol"},{"issue":"2","key":"2024070101015365900_ref4","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s00345-019-02818-3","article-title":"Sixty years in the making: collagenase Clostridium histolyticum, from benchtop to FDA approval and beyond","volume":"38","author":"Mills","year":"2020","journal-title":"World J Urol"},{"issue":"9","key":"2024070101015365900_ref5","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1517\/14712598.2010.510509","article-title":"Collagenase Clostridium histolyticum for Dupuytren\u2019s contracture","volume":"10","author":"Desai","year":"2010","journal-title":"Expert Opin Biol Ther"},{"issue":"2","key":"2024070101015365900_ref6","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s00345-019-02812-9","article-title":"A modified technique for intralesional injection of collagenase Clostridium histolyticum for Peyronie\u2019s disease results in reduced procedural morbidity using a standardized hematoma classification rubric","volume":"38","author":"Amighi","year":"2020","journal-title":"World J Urol"},{"issue":"2","key":"2024070101015365900_ref7","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s00345-019-03055-4","article-title":"Peyronie\u2019s disease in contemporary urological practice","volume":"38","author":"Mills","year":"2020","journal-title":"World J Urol"},{"issue":"2","key":"2024070101015365900_ref8","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s00345-019-02817-4","article-title":"Managing complications of collagenase Clostridium histolyticum (CCH) injection","volume":"38","author":"Greear","year":"2020","journal-title":"World J Urol"},{"issue":"5","key":"2024070101015365900_ref9","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1097\/JU.0000000000003634","article-title":"Comparison of collagenase Clostridium histolyticum to surgery for the management of Peyronie\u2019s disease: a randomized trial","volume":"210","author":"Green","year":"2023","journal-title":"J Urol"},{"issue":"1","key":"2024070101015365900_ref10","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.juro.2013.01.087","article-title":"Clinical efficacy, safety and tolerability of collagenase Clostridium histolyticum for the treatment of Peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies","volume":"190","author":"Gelbard","year":"2013","journal-title":"J Urol"},{"key":"2024070101015365900_ref11","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.urology.2017.01.054","article-title":"Clinical experience with penile traction therapy among men undergoing collagenase Clostridium histolyticum for Peyronie\u2019s disease","volume":"104","author":"Ziegelmann","year":"2017","journal-title":"Urology"},{"key":"2024070101015365900_ref12","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.urology.2016.09.050","article-title":"Impact of number of cycles of collagenase Clostridium histolyticum on outcomes in patients with Peyronie\u2019s disease","volume":"100","author":"Anaissie","year":"2017","journal-title":"Urology"},{"issue":"5","key":"2024070101015365900_ref13","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/bju.13932","article-title":"Safety and effectiveness of collagenase Clostridium histolyticum in the treatment of Peyronie\u2019s disease using a new modified shortened protocol","volume":"120","author":"Abdel Raheem","year":"2017","journal-title":"BJU Int"},{"issue":"10","key":"2024070101015365900_ref14","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/j.jsxm.2017.08.008","article-title":"Safety and efficacy of collagenase Clostridium histolyticum in the treatment of acute-phase Peyronie\u2019s disease","volume":"14","author":"Nguyen","year":"2017","journal-title":"J Sex Med"},{"issue":"5","key":"2024070101015365900_ref15","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/bju.13120","article-title":"Analysis of the clinical safety of intralesional injection of collagenase Clostridium histolyticum (CCH) for adults with Peyronie\u2019s disease (PD)","volume":"116","author":"Carson","year":"2015","journal-title":"BJU Int"},{"issue":"2","key":"2024070101015365900_ref16","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.sxmr.2017.07.011","article-title":"Intralesional injection of collagenase Clostridium histolyticum may increase the risk of late-onset penile fracture","volume":"6","author":"Beilan","year":"2018","journal-title":"Sex Med Rev"},{"key":"2024070101015365900_ref17","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.urology.2016.04.049","article-title":"Peyronie\u2019s disease and injectable collagenase Clostridium histolyticum: safety, efficacy, and improvements in subjective symptoms","volume":"94","author":"Yang","year":"2016","journal-title":"Urology"},{"issue":"6","key":"2024070101015365900_ref18","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1016\/j.juro.2012.01.032","article-title":"Phase 2b study of the clinical efficacy and safety of collagenase Clostridium histolyticum in patients with Peyronie disease","volume":"187","author":"Gelbard","year":"2012","journal-title":"J Urol"},{"issue":"3","key":"2024070101015365900_ref19","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1159\/000444399","article-title":"Acute ischemia of the glans penis after circumcision treated with hyperbaric therapy and pentoxifylline: case report and revision of the literature","volume":"100","author":"Migliorini","year":"2016","journal-title":"Urol Int"},{"issue":"4","key":"2024070101015365900_ref20","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1097\/JU.0000000000002789","article-title":"Acute lower back pain after intralesional injection of collagenase Clostridium histolyticum for Peyronie\u2019s disease","volume":"208","author":"Sigalos","year":"2022","journal-title":"J Urol"},{"issue":"2","key":"2024070101015365900_ref21","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s11934-020-01025-7","article-title":"The management of penile fracture: a review of the literature with special consideration for patients undergoing collagenase Clostridium histolyticum injection therapy","volume":"22","author":"Hughes","year":"2021","journal-title":"Curr Urol Rep"},{"issue":"1","key":"2024070101015365900_ref22","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/s41443-020-00383-7","article-title":"Conservative management of suspected fractures in men undergoing collagenase Clostridium histolyticum for Peyronie\u2019s disease is not associated with worsening of erectile function","volume":"34","author":"Sharma","year":"2022","journal-title":"Int J Impot Res"},{"issue":"2","key":"2024070101015365900_ref23","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jsxm.2019.11.002","article-title":"Safety of collagenase Clostridium histolyticum injection therapy for Peyronie disease in patients continuing antiplatelet or anticoagulant therapy","volume":"17","author":"Amighi","year":"2020","journal-title":"J Sex Med"},{"issue":"4","key":"2024070101015365900_ref24","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.sxmr.2019.05.001","article-title":"Discontinuation from collagenase Clostridium histolyticum therapy for Peyronie\u2019s disease: review and single-Center cohort analysis","volume":"7","author":"Amighi","year":"2019","journal-title":"Sex Med Rev"},{"issue":"1","key":"2024070101015365900_ref25","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/s41443-020-0311-z","article-title":"Impact of treatment-related adverse events on efficacy of intralesional collagenase therapy for Peyronie\u2019s disease","volume":"33","author":"Walker","year":"2021","journal-title":"Int J Impot Res"}],"container-title":["Sexual Medicine Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/smr\/article-pdf\/12\/3\/491\/58335013\/qeae004.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/smr\/article-pdf\/12\/3\/491\/58335013\/qeae004.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T01:03:41Z","timestamp":1719795821000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/smr\/article\/12\/3\/491\/7630113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,15]]},"references-count":25,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3,15]]},"published-print":{"date-parts":[[2024,6,26]]}},"URL":"https:\/\/doi.org\/10.1093\/sxmrev\/qeae004","relation":{},"ISSN":["2050-0513","2050-0521"],"issn-type":[{"value":"2050-0513","type":"print"},{"value":"2050-0521","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,7]]},"published":{"date-parts":[[2024,3,15]]}}}